Mice that make heavy chain antibodies
    53.
    发明授权
    Mice that make heavy chain antibodies 有权
    产生重链抗体的小鼠

    公开(公告)号:US08754287B2

    公开(公告)日:2014-06-17

    申请号:US12965050

    申请日:2010-12-10

    摘要: Genetically modified non-human animals and methods and compositions for making and using them are provided, wherein the genetic modification comprises a deletion in an immunoglobulin constant region CH1 gene (optionally a deletion in a hinge region) of an IgG, IgA, IgD, and/or IgE, and wherein the mouse is capable of expressing a functional IgM. Genetically modified mice are described, including mice having a functional IgM gene and modified to have a deletion of a CH1 domain and a hinge region in a heavy chain constant domain that is not an IgM, e.g., in an IgG heavy chain constant domain. Genetically modified mice that make human variable/mouse constant chimeric heavy chain antibodies (antibodies that lack a light chain), fully mouse heavy chain antibodies, or fully human heavy chain antibodies are provided.

    摘要翻译: 提供了遗传修饰的非人动物以及用于制备和使用它们的方法和组合物,其中遗传修饰包括IgG,IgA,IgD和/或IgG的免疫球蛋白恒定区CH1基因(任选地在铰链区的缺失)中的缺失 /或IgE,并且其中所述小鼠能够表达功能性IgM。 描述了遗传修饰的小鼠,包括具有功能性IgM基因的小鼠,并且被修饰为具有不是IgM的重链恒定结构域中的CH1结构域和铰链区的缺失,例如在IgG重链恒定结构域中。 提供了使人可变/小鼠恒定的嵌合重链抗体(缺乏轻链的抗体),完全小鼠重链抗体或完全人重链抗体的转基因小鼠。

    Neuropeptide release assay for sodium channels
    55.
    发明授权
    Neuropeptide release assay for sodium channels 有权
    钠通道神经肽释放测定

    公开(公告)号:US08486647B2

    公开(公告)日:2013-07-16

    申请号:US13236117

    申请日:2011-09-19

    CPC分类号: C07K14/435

    摘要: Methods and compositions for using genetically modified non-human animals are provided, wherein the genetic modification comprises a humanization of the one or more extracellular pore loops of a NaV1.7 channel protein or a complete humanization of an endogenous NaV1.7 gene. Methods for using isolated DRG cultures from genetically modified non-human animals are also provided, wherein the isolated DRG express a human or chimeric NaV1.7 protein on the surface, in particular measuring primary nociceptive activation through the release of calcitonin gene-related peptide (CGRP) in isolated DRG in vitro, and wherein the isolated DRG cultures are capable of generating action potentials and communicating through an excitable signal via the expressed human or chimeric NaV1.7 protein the cell surface. In vivo and in vitro methods for characterizing NaV1.7-specific antagonists and evaluation of corresponding therapeutic potential for NaV1.7-mediated disease are also provided.

    摘要翻译: 提供了使用遗传修饰的非人动物的方法和组合物,其中遗传修饰包括NaV1.7通道蛋白的一个或多个胞外孔环的人源化或内源性NaV1.7基因的完全人源化。 还提供了使用来自遗传修饰的非人动物的分离的DRG培养物的方法,其中分离的DRG在表面上表达人或嵌合的NaV1.7蛋白,特别是通过释放降钙素基因相关肽测量初级伤害感受激活( CGRP),其中分离的DRG培养物能够产生动作电位并通过表达的人或嵌合的NaV1.7蛋白的细胞表面通过可兴奋的信号传递。 还提供了用于表征NaV1.7特异性拮抗剂的体内和体外方法以及对NaV1.7介导的疾病的相应治疗潜力的评估。

    Common Light Chain Mouse
    56.
    发明申请
    Common Light Chain Mouse 审中-公开
    普通轻链鼠标

    公开(公告)号:US20120192300A1

    公开(公告)日:2012-07-26

    申请号:US13412936

    申请日:2012-03-06

    IPC分类号: A01K67/027

    摘要: A genetically modified mouse is provided, wherein the mouse expresses an immunoglobulin light chain repertoire characterized by a limited number of light chain variable domains. Mice are provided that express just one or a few immunoglobulin light chain variable domains from a limited repertoire in their germline. Methods for making light chain variable regions in mice, including human light chain variable regions, are provided. Methods for making human variable regions suitable for use in multispecific binding proteins, e.g., bispecific antibodies, are provided.

    摘要翻译: 提供遗传修饰的小鼠,其中小鼠表达免疫球蛋白轻链总谱,其特征在于有限数量的轻链可变结构域。 提供的小鼠在其种系中仅来自有限谱系的一个或几个免疫球蛋白轻链可变结构域。 提供了在小鼠中制备轻链可变区的方法,包括人轻链可变区。 提供了适用于多特异性结合蛋白(例如双特异性抗体)的人可变区的方法。

    Mice That Make VL Binding Proteins
    57.
    发明申请
    Mice That Make VL Binding Proteins 有权
    使VL结合蛋白的小鼠

    公开(公告)号:US20120096572A1

    公开(公告)日:2012-04-19

    申请号:US13195951

    申请日:2011-08-02

    IPC分类号: A01K67/027

    摘要: Genetically modified mice and methods for making an using them are provided, wherein the mice comprise a replacement of all or substantially all immunoglobulin heavy chain V gene segments, D gene segments, and J gene segments with at least one light chain V gene segment and at least one light chain J gene segment. Mice that make binding proteins that comprise a light chain variable domain operably linked to a heavy chain constant region are provided. Binding proteins that contain an immunoglobulin light chain variable domain, including a somatically hypermutated light chain variable domain, fused with a heavy chain constant region, are provided. Modified cells, embryos, and mice that encode sequences for making the binding proteins are provided.

    摘要翻译: 提供遗传修饰的小鼠和使用它们的方法,其中小鼠包含用至少一个轻链V基因区段替换全部或基本上所有的免疫球蛋白重链V基因区段,D基因区段和J基因区段, 至少一条轻链J基因片段。 提供了产生结合蛋白质的小鼠,其包含可操作地连接到重链恒定区的轻链可变结构域。 提供了与重链恒定区融合的含有免疫球蛋白轻链可变结构域的结合蛋白,包括体细胞超突变的轻链可变结构域。 提供编码用于制备结合蛋白的序列的修饰的细胞,胚胎和小鼠。

    Methods and compositions for identifying receptor effectors
    60.
    发明授权
    Methods and compositions for identifying receptor effectors 失效
    用于鉴定受体效应物的方法和组合物

    公开(公告)号:US07319009B2

    公开(公告)日:2008-01-15

    申请号:US10277607

    申请日:2002-10-22

    CPC分类号: C07K14/723

    摘要: The present invention makes available rapid, effective assays for screening and identifying pharmaceutically effective compounds that specifically interact with and modulate the activity of a cellular receptor or ion channel. The subject assays enable rapid screening of large numbers of polypeptides in a library to identify those polypeptides which induce or antagonize receptor bioactivity. The subject assays are particularly amenable for identifying agonists and antagonists for orphan receptors. In particular the present invention makes available novel ligand agonists of human formyl peptide receptor like-1 (FPRL-1) receptors. These novel ligand agonists are used in the assays of the invention to identify modulators of FPRL-1 receptor.

    摘要翻译: 本发明提供用于筛选和鉴定与细胞受体或离子通道的活性特异性相互作用并调节其活性的药学有效化合物的快速有效的测定。 本发明的分析使得能够快速筛选文库中的大量多肽,以鉴定诱导或拮抗受体生物活性的那些多肽。 主题测定特别适用于鉴定孤儿受体的激动剂和拮抗剂。 特别地,本发明提供人类甲酰肽受体1(FPRL-1)受体的新型配体激动剂。 这些新型配体激动剂用于本发明的测定以鉴定FPRL-1受体的调节剂。